2023
Mortality, incarceration and cost implications of fentanyl felonization laws: A modeling study
Savinkina A, Jurecka C, Gonsalves G, Barocas J. Mortality, incarceration and cost implications of fentanyl felonization laws: A modeling study. International Journal Of Drug Policy 2023, 121: 104175. PMID: 37729682, PMCID: PMC10840895, DOI: 10.1016/j.drugpo.2023.104175.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidDrug OverdoseFentanylHumansOpiate OverdoseOpioid-Related DisordersUnited StatesEconomic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
Flam-Ross J, Marsh E, Weitz M, Savinkina A, Schackman B, Wang J, Madushani R, Morgan J, Barocas J, Walley A, Chrysanthopoulou S, Linas B, Assoumou S. Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder. JAMA Network Open 2023, 6: e2329583. PMID: 37703018, PMCID: PMC10500382, DOI: 10.1001/jamanetworkopen.2023.29583.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineCost-Benefit AnalysisFemaleHumansMaleMiddle AgedOpioid-Related DisordersPatient Acceptance of Health CareUnited StatesConceptsExtended-release buprenorphineIncremental cost-effectiveness ratioMedication treatmentHealth care utilization costsTreatment of OUDOpioid agonist treatmentOpioid use disorderMean lifetime costsCost-effectiveness ratioProbabilistic sensitivity analysesEconomic evaluationCohort studyAgonist treatmentTreatment optionsClinical trialsClosed cohortMAIN OUTCOMEBuprenorphineSimulated cohortUse disordersDrug AdministrationUS FoodPharmaceutical costsQALY willingnessInjectable formEstimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts
Chatterjee A, Weitz M, Savinkina A, Macmadu A, Madushani R, Potee R, Ryan D, Murphy S, Walley A, Linas B. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts. JAMA Network Open 2023, 6: e237036. PMID: 37058306, PMCID: PMC10105308, DOI: 10.1001/jamanetworkopen.2023.7036.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBuprenorphineDrug OverdoseHumansMassachusettsNaltrexoneOpioid-Related DisordersConceptsIncremental cost-effectiveness ratioIncremental costCost-effectiveness ratioEconomic evaluationEconomic studiesOpioid use disorderXR-naltrexoneOverdose deathsTreatment startQALYOverdose mortalityUse disordersCostExtended-release naltrexoneTreatment costsDiscontinue medicationsMOUD accessQALYsOpen cohortMost prisonsIncarcerated individualsMOUD treatmentTreatment strategiesMoneyFatal overdoses
2022
Population‐level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost‐effectiveness analysis
Savinkina A, Madushani RWMA, Yazdi G, Wang J, Barocas JA, Morgan JR, Assoumou SA, Walley AY, Linas BP, Murphy SM. Population‐level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost‐effectiveness analysis. Addiction 2022, 117: 2450-2461. PMID: 35315162, PMCID: PMC9377514, DOI: 10.1111/add.15879.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBuprenorphineCost-Benefit AnalysisDrug OverdoseHumansInpatientsOpiate Substitution TreatmentOpioid-Related DisordersUnited StatesConceptsIncremental cost-effectiveness ratioOpioid use disorderStandard of careUse disordersFatal overdosesDetox patientsMOUD initiationWithdrawal programInitiation of medicationHealth care sector perspectiveRisk of overdoseFatal opioid overdosesCost-effectiveness ratioCost-effectiveness analysisOpioid useHealth care spendingOutpatient careDetox programsOpioid overdosesMOUDPatientsOverdosesPopulation-level impactDisorder populationHealth effectsModeling the cost‐effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs
Adams JW, Savinkina A, Fox A, Behrends CN, Madushani RWMA, Wang J, Chatterjee A, Walley AY, Barocas JA, Linas BP. Modeling the cost‐effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs. Addiction 2022, 117: 2635-2648. PMID: 35315148, PMCID: PMC9951221, DOI: 10.1111/add.15883.Peer-Reviewed Original ResearchConceptsSyringe services programFatal opioid overdosesBuprenorphine-naloxone treatmentOpioid use disorderTreatment initiationBuprenorphine treatmentOpioid overdosesFatal overdosesSSP clientsActive opioid useCommunity treatment providersObservational cohort studyNational surveillance dataCost-effectiveness analysisCohort studyIntervention scenariosOpioid useBuprenorphine programOUD treatmentStatus quo scenarioClinical trialsFatal overdoseMore QALYsUse disordersTreatment engagement
2021
Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study
Barocas JA, Savinkina A, Adams J, Jawa R, Weinstein ZM, Samet JH, Linas BP. Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study. The Lancet Public Health 2021, 7: e56-e64. PMID: 34861189, PMCID: PMC8756295, DOI: 10.1016/s2468-2667(21)00248-6.Peer-Reviewed Original ResearchConceptsOpioid use disorderAddiction consult serviceHospital-based strategiesUS opioid epidemicOpioid epidemicUse disordersConsult serviceProbabilistic sensitivity analysesClinical impactDrug useIncremental cost-effectiveness ratioInjection-related infectionsInjection drug useMean lifetime costsNational InstituteCost-effectiveness ratioHarm reduction servicesDeterministic sensitivity analysesInpatient prescribingObservational cohortRecurrent infectionsOutpatient treatmentClinical trialsOverdose riskMedications
2020
A clash of epidemics: Impact of the COVID-19 pandemic response on opioid overdose
Linas BP, Savinkina A, Barbosa C, Mueller PP, Cerdá M, Keyes K, Chhatwal J. A clash of epidemics: Impact of the COVID-19 pandemic response on opioid overdose. Journal Of Substance Use And Addiction Treatment 2020, 120: 108158. PMID: 33298298, PMCID: PMC7536128, DOI: 10.1016/j.jsat.2020.108158.Peer-Reviewed Original ResearchMeSH KeywordsComputer SimulationCOVID-19HumansMental HealthOpiate OverdoseOpioid-Related DisordersPatient Acceptance of Health CarePhysical DistancingPublic HealthQuarantineConceptsOpioid use disorderCOVID-19 infectionCoronavirus disease 2019COVID-19Treatment-seeking behaviorPhysical distancingCOVID-19 pandemic responseOpioid epidemicDisease 2019Overdose mortalityUse disordersGreater substance usePhysical distancing interventionsMental healthQuarantine interventionSubstance useDrug supplyPandemic responsePublic healthHealthInterventionEpidemicDirect effectPossible mechanismOpioidsLong-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study
Barocas JA, Yazdi G, Savinkina A, Nolen S, Savitzky C, Samet JH, Englander H, Linas BP. Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study. Clinical Infectious Diseases 2020, 73: e3661-e3669. PMID: 32901815, PMCID: PMC8662770, DOI: 10.1093/cid/ciaa1346.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidEndocarditisEndocarditis, BacterialHumansInjectionsMaleMiddle AgedOpioid-Related DisordersSubstance Abuse, IntravenousUnited StatesConceptsInjection opioid useRisk of deathAge 60 yearsOpioid useInfective endocarditisOpioid epidemicMortality rateUS opioid epidemicSyringe services programLow-risk techniqueProbability of deathHarm reduction approachAttributable fractionRisk groupsNatural historyInjection behaviorModel-generated estimatesDeathOpioidsSignificant increaseInjection frequencyUnited StatesMortalityRiskEpidemic